Combination of two oral drugs for previously treated Waldenström macroglobulinemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have received at least one previous treatment for Waldenström macroglobulinemia, but not a BTK inhibitor or a Bcl-2 antagonist.
- You are generally able to carry out daily activities (ECOG score 0–3).
- Your kidney and liver function are within acceptable limits (creatinine clearance ≥ 50 mL/min, and liver enzymes below certain levels).
- Your blood counts (neutrophils and platelets) meet minimum thresholds.
- You have not had a recent heart attack or serious heart rhythm problem, and your heart's pumping function is not severely reduced.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This study tests a combination of new and older drugs for Waldenström macroglobulinemia, a rare blood cancer. The drugs aim to block the cancer's growth signals and boost the body's immune attack. It is for people who have not yet had any treatment for this condition.
This study is testing a combination of two medicines (zanubrutinib and BR) as the first treatment for patients with Waldenström's macroglobulinemia. The goal is to see if this combination works well and is safe for people who have not been treated before.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.